Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Edith A . Perez, M.D.

Back to Research Profile

  1. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 2009 Nov 09. [Epub ahead of print]
    View PubMed
  2. Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ, Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA. Reply to N. Magne et al. J Clin Oncol 2009 Nov 02. [Epub ahead of print]
    View PubMed
  3. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009 Oct; 117(3):603-9. Epub 2009 Feb 12.
    View PubMed
  4. Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol 2009 Sep 15. [Epub ahead of print]
    View PubMed
  5. Perez EA. Management Recommendations for Adjuvant Systemic Breast Cancer Therapy. Breast Dis 2009 Sep 03; 21:15-21. [Epub ahead of print]
    View PubMed
  6. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol 2009 Aug 1; 27(22):3620-6. Epub 2009 Jun 01.
    View PubMed
  7. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009 Aug; 8(8):2086-95. Epub 2009 Aug 11.
    View PubMed
  8. Moreno-Avpitia M, Perez EA. Anthracycline- and/or Taxane-Resistant Breast Cancer: Results of a Literature Review to Determine the Clinical Challenges and Current Treatment Trends. Clinical Therapeutics 2009 August; 31(8):1619-1640.
    View PubMed
  9. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009 Aug; 31(8):1619-40.
    View PubMed
  10. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol 2009 Jul 22. [Epub ahead of print]
    View PubMed
  11. Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat 2009 Jul; 116(1):31-8. Epub 2008 Dec 20.
    View PubMed
  12. Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL. Recommendations for Research Priorities in Breast Cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: Systemic Therapy and Therapeutics Individualization. Breast Cancer Res Treat 2009 June 14.
    View PubMed
  13. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009 Jun 1; 27(16):2638-44. Epub 2009 Apr 06.
    View PubMed
  14. Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck AC, Perez EA, Halyard MY, Frost MH, Cheville AL, Sloan JA. Quality of life after breast cancer surgery: What have we learned and where should we go next? J Surg Oncol 2009 Jun 1; 99(7):447-55.
    View PubMed
  15. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009 Jun; 84(6):533-45.
    View PubMed
  16. Muss HB, Berry DA, Cirrincion CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. New Eng J Med 2009 May 14; 260(20):2055-2065.
    View PubMed
  17. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones M, Moore HCF, Jin LX, Warsi GM, Ericson SG, Perez EA. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: z-fast study 36-month follow-up results. Clinical Breast Cancer 2009 May; 9(2):77-85.
    View PubMed
  18. Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol 2009 Apr; 4(4):479-85.
    View PubMed
  19. Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Chewar DM, Abaya R, Colon-Otero G, Perez EA. Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population. Mayo Clin Proc 2009 Apr; 84(4):317-22.
    View PubMed
  20. Amar S, Roy V, Perez EA. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 2009 Apr; 114(3):413-22. Epub 2008 May 09.
    View PubMed
  21. Hines SL, Tan WW, Moreno-Aspitia A, Roy V, Vallow LA, McLaughlin SA, Perez EA. A Practical Clinical Approach to Adjuvant Therapy in Breast Cancer - An Update. US Oncol 2009 Apr; 20:49-53.
    View PubMed
  22. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009 Mar 1; 27(7):1047-53. Epub 2008 Dec 15.
    View PubMed
  23. Perez EA. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 2009 Mar; 114(2):195-201. Epub 2008 Apr 29.
    View PubMed
  24. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009 Mar; 10(3):267-77.
    View PubMed
  25. Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009 Jan 1; 27(1):11-5. Epub 2008 Dec 01.
    View PubMed
  26. Perez EA, Palmieri FM, Brock SM. Trastuzumab. Cancer Treat Res 2009; 151:181-96.
    View PubMed
  27. Soto E, Yanagisawa M, Marlow LA, Copland JA, Perez EA, Anastasiadis PZ. p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression. J Cell Biol 2008 Nov 17; 183(4):737-49.
    View PubMed
  28. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008 Oct 1; 26(28):4672-8.
    View PubMed
  29. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central Cancer Treatment Group. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol 2008 Oct; 35(5):530-44.
    View PubMed
  30. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008 Sep 15; 14(18):5864-8.
    View PubMed
  31. Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197. J Clin Oncol 2008 Sep 1; 26(25):4092-9.
    View PubMed
  32. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge Jr GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared with Classical Clinicopathologic Features. J Clin Oncol 2008 Sept; 26(25):4063-4071.
    View PubMed
  33. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008 Sep; 19(9):1561-5. Epub 2008 Jun 05.
    View PubMed
  34. Perez EA, Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest 2008 Jul; 26(6):545-52.
    View PubMed
  35. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008 Jul; 19(7):1231-41.
    View PubMed
  36. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering Committee, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008 Jul; 19(7):1231-41. Epub 2008 Mar 05.
    View PubMed
  37. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008 Jun; 83(6):679-86.
    View PubMed
  38. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008 May; 19(5):877-82. Epub 2008 Mar 10.
    View PubMed
  39. Amar S, Moreno-Aspitia A, Perez EA. Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2008 May; 109(1):1-7. Epub 2007 Jul 26.
    View PubMed
  40. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008 May; 13(5):503-14.
    View PubMed
  41. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008 May; 13(5):503-14.
    View PubMed
  42. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 2008 May; 60(2):200-7. Epub 2007 Nov 28.
    View PubMed
  43. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M-L, Rowley SC, Shak S, Perez EA, Shalman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and Progesterone- Receptor Status in ECOG 2197: Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. J Clin Oncol 2008 May; 26(15):2473-2481.
    View PubMed
  44. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008 Apr 20; 26(12):1948-55. Epub 2008 Mar 10.
    View PubMed
  45. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly Paclitaxel in teh Adjuvant Treatment of Breast Cancer. N Engl J Med 2008 April 17; 358(16):1663-1671.
    View PubMed
  46. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008 Mar 10; 26(8):1231-8. Epub 2008 Feb 04.
    View PubMed
  47. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 2008 Mar; 8 Suppl 3:S114-20.
    View PubMed
  48. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer 2008 Feb; 8(1):33-7.
    View PubMed
  49. Perez EA. Modulating Drug Resistance in Metastatic Breast Cancer. Commun Oncol 2008; 5(suppl 3):2-9.
    View PubMed
  50. Colong-Otero G, King S, Smith V, Bieber C, Crook J, Solberg LA, Shannon R, Perez EA. Increased Incidence of Loco-Regional Recurrences Among African American Women with Terminal Stage Breast Cancer. Clin Med Oncol 2008; 2:1-4.
    View PubMed
  51. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27; 357(26):2666-76.
    View PubMed
  52. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer 2007 Oct 1; 110(7):1629-40.
    View PubMed
  53. Pruthi S, Boughey JC, Brandt KR, Degnim AC, Dy GK, Goetz MP, Perez EA, Reynolds CA, Schomberg PJ, Ingle JN. A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc 2007 Sep; 82(9):1131-40.
    View PubMed
  54. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007 Sep; 18 Suppl 8:viii26-35.
    View PubMed
  55. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007 Aug 10; 25(23):3407-14. Epub 2007 Jul 02.
    View PubMed
  56. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007 Aug 1; 110(3):489-98.
    View PubMed
  57. Pruthi S, Brandt KR, Degnem AC, Goetz MP, Perez EA, Reynolds CA, Schomberg PJ, Dy GK, Ingle JN. A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc 2007 Aug; 82(8):999-1012.
    View PubMed
  58. Pruthi S, Brandt KR, Degnim AC, Goetz MP, Perez EA, Reynolds CA, Schomberg PJ, Dy GK, Ingle JN. A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc 2007 Aug; 82(8):999-1012.
    View PubMed
  59. Perez EA. Novel enhanced delivery taxanes: an update. Semin Oncol 2007 Jun; 34(3):suppl 1-5.
    View PubMed
  60. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL, National Cancer Institute of Canada Clinical Trials G Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007 May 20; 25(15):2006-11 Epub 2007 Apr 23.
    View PubMed
  61. Halyard MY, Jatoi A, Sloan JA, Bearden JD 3rd, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 2007 Apr 1; 67(5):1318-22.
    View PubMed
  62. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007 Mar 1; 25(7):829-36.
    View PubMed
  63. Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc 2007 Mar; 82(3):297-300.
    View PubMed
  64. Palmieri FM, Perez EA. Managing high-risk breast cancer. Semin Oncol Nurs 2007 Feb; 23(1):29-36.
    View PubMed
  65. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007 Jan 1; 25(1):118-45. Epub 2006 Dec 11.
    View PubMed
  66. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007 Jan; 101(1):113-21. Epub 2006 Nov 18.
    View PubMed
  67. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred C, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer Am McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology / College of American Pathologist Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007; 25(1):118-145.
    View PubMed
  68. Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat 2007; 105 Suppl 1:75-89. Epub 2007 Oct 03.
    View PubMed
  69. Perez EA. Appraising adjuvant aromatase inhibitor therapy. Oncologist 2006 Nov-Dec; 11(10):1058-69.
    View PubMed
  70. Ingle JN, Tu DS, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchards KI, Livingston RB, Davidsonlo NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCICCTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006 Oct; 99(3):295-300.
    View PubMed
  71. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006 Oct; 99(3):295-300. Epub 2006 Mar 16.
    View PubMed
  72. Perez EA. The balance between risks and benefits: Long-term use of aromatase inhibitors. European Journal of Cancer Supplement 1990 2006 Sep; 4(9):16-25.
  73. Perez EA, Jesse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu SF, Tu DS, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCICCTG MA.17. J Clin Oncol 2006 Aug 1; 24(22):3629-35.
    View PubMed
  74. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006 Aug 1; 24(22):3629-35. Epub 2006 Jul 05.
    View PubMed
  75. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006 Aug; 20(9):1029-39; discussion 1039-40, 1042, 1048.
    View PubMed
  76. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006 Jul 1; 24(19):3032-8.
    View PubMed
  77. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat 2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
    View PubMed
  78. Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006 Jun; 7(2):127-32.
    View PubMed
  79. Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin Oncol 2006 Jun; 33(3 Suppl 9):S3-8.
    View PubMed
  80. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006 Apr 12; 295(14):1658-67.
    View PubMed
  81. Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 2006 Apr 1; 12(7 Pt 1):2080-7.
    View PubMed
  82. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients >= 65 years of age: an NCCTG study. Ann Oncol 2006 Apr; 17(4):623-9.
    View PubMed
  83. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA, Ncctg. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol 2006 Apr; 17(4):623-9. Epub 2006 Mar 06.
    View PubMed
  84. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA, North Central Cancer Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006 Mar 1; 24(7):1052-6.
    View PubMed
  85. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PAS, Nikcevich DA, Perez EA. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group trial N0032. J Clin Oncol 2006 Mar 1; 24(7):1052-6.
    View PubMed
  86. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, National Comprehensive Cancer Network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006 Mar; 4 Suppl 1:S1-26.
    View PubMed
  87. Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol 2006 Feb; 17(2):226-31. Epub 2005 Nov 22.
    View PubMed
  88. Roy V, Perez EA. Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer. Cancer Treat Rev 2006 Feb; 32(1):55-8. Epub 2006 Jan 19.
    View PubMed
  89. Wirk B, Perez E. Role of gemcitabine in breast cancer management: an update. Semin Oncol 2006 Feb; 33(1 Suppl 2):S6-14.
    View PubMed
  90. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC. NCCN Task Force Report: Adjuvant therapy for breast cancer. J Natl Compr Cancer Netw 2006; 4(Suppl 1):S1-26.
  91. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11 Suppl 1:4-12.
    View PubMed
  92. Perez EA. Other significant research and future directions. Clinical Advances in Hematology and Oncology 2006; 4(3 Suppl 7):8-9.
    View PubMed
  93. Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B, Schild SE, Castillo R, Jett JR. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005 Dec 20; 23(36):9113-9.
  94. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 Dec 20; 23(36):9312-8.
  95. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncology 2005 Dec; 1(6):755-62.
    View PubMed
  96. Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Huntington) 2005 Dec; 19(14):1759-67; discussion 1768, 1772-4, 1777-8.
    View PubMed
  97. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005 Dec; 6(5):425-32.
    View PubMed
  98. Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Huntington) 2005 Dec; 19(14):1759-67.
    View PubMed
  99. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol 2005 Dec; 1(6):755-62.
    View PubMed
  100. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein P Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 2005 Oct 20; 353(16):1673-84.
    View PubMed
  101. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005 Oct; 10(9):665-85.
    View PubMed
  102. Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer 2005 Oct; 6(4):361-4.
    View PubMed
  103. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu DS, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCICCTG MA.17. J Natl Cancer Inst 2005 Sep 7; 97(17):1262-71.
    View PubMed
  104. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 2005 Jun; 23(3):257-61.
    View PubMed
  105. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath A, DeAngelis D, Perez EA. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005 May; 16(5):707-15.
    View PubMed
  106. Lafky JM, Baron LT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 2005 Apr 15; 65(8):3059-62.
    View PubMed
  107. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer-a North Central Cancer Treatment Group trial. Am J Clin Oncol: Cancer Clin Trials 2005 Apr; 28(2):195-200.
  108. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005 Apr; 12(2):73-81.
    View PubMed
  109. Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PWT, Saltz L, Schapira L, Sparano J. ACCO: ASCO core curriculum outline. J Clin Oncol 2005 Mar 20; 23(9):2049-77.
    View PubMed
  110. Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology 2005; 69(2):117-21.
    View PubMed
  111. Perez EA. Trastuzumab as part of adjuvant therapy for patients with HER2-positive breast cancer. The Amer J of Oncol Review 2005; 4(11 Suppl 15):11-3.
  112. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu DS, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCI NCCTG MA. J Natl Cancer Inst 2005; 97(17):1262-71.
  113. McDonough RF, Perez EA. Medical Oncology and the treatment of breast cancer. North East Florida Medical Journal 2005.
  114. Tack DK, Palmieri FM, Perez EA. Anthracycline vs nonanthracycline adjuvant theray for breast cancer. Oncology (Huntington) 2004 Oct; 18(11):1367-76.
    View PubMed
  115. Perez EA, Pusztai L, van De Vijver M. Improving patient care through molecular diagnostics. Semin Oncol 2004 Oct; 31(5 Suppl 10):14-20.
    View PubMed
  116. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004 Oct; 31(5 Suppl 10):51-7.
    View PubMed
  117. Tack DK, Palmieri FM, Perez EA. Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Oncology (Huntington) 2004 Oct; 18(11):1367-76; discussion 1378, 1381.
    View PubMed
  118. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2004 Sep 15; 22(18):3700-4.
    View PubMed
  119. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. Program/Proceedings of the American Society of Clinical Oncology 2004 Jul 15; 22(14):2849-55.
  120. Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW. Utilizing Nottingham prognostic index in microarray gene expression profiling of breast carcinomas. Mod Pathol 2004 Jul; 17(7):756-64.
    View PubMed
  121. Mincey BA, Perez EA. Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc 2004 Jun; 79(6):810-6.
    View PubMed
  122. Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH, Tazelarr HD, Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer 2004 Jun; 44(3):347-53.
    View PubMed
  123. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004 Jan 15; 22(2):322-9.
    View PubMed
  124. Perez EA. Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2004 Jan; 4 Suppl 3:S113-6.
    View PubMed
  125. Perez EA, Robert NJ, Tripathy D. Trastuzumab in adjuvant therapy for breast cancer. The American Journal of Oncology Review 2004; 3(6 Suppl 4):12-4.
  126. Perez EA. Management recommendations for adjuvant systemic breast cancer therapy. Breast Dis 2004; 21:15-21.
    View PubMed
  127. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004; 9(5):518-27.
    View PubMed
  128. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349(19):1793-802.
    View PubMed
  129. Palmieri FM, Perez EA. Recent advances in adjuvant therapy for breast cancer. Semin Oncol Nurs 2003 Nov; 19(4 Suppl 2):10-6.
    View PubMed
  130. Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol 2003 Oct; 26(5):441-7.
    View PubMed
  131. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and J Clin Oncol 2003 Apr 15; 21(8):1431-9.
    View PubMed
  132. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 2003 Mar 1; 21(5):864-70.
    View PubMed
  133. Perez E. Adjuvant chemotherapy: controversies and the role of taxanes. Breast J 2003 Jan-Feb; 9 Suppl 1:S25-8.
  134. Perez EA. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated? Curr Oncol Rep 2003 Jan; 5(1):66-71.
    View PubMed
  135. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest 2003; 21(1):1-6.
    View PubMed
  136. Loprinzi CL, Barton DL, Sloan JA, Zahasky KM, Smith DR, Pruthi S, Novotny PJ, Perez EA, Christensen BJ. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002 Nov; 77(11):1159-63.
    View PubMed
  137. Perez EA. Exploring newer chemotherapeutic and targeted biologic regimens for patients with advanced and metastatic breast cancer. Medscape CME Circle 2002 Sept 20; URL:http.//www.medscape.com
  138. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 2002 Aug; 13(8):1225-35.
    View PubMed
  139. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Determination of HER2 status for the Breast Intergroup Trial N9831: Preliminary results of concordance between community and central Laboratory testing and the correlation of overexpression and amplification. J Natl Cancer Inst 2002 Jun 5; 94(11):855-7.
    View PubMed
  140. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst 2002 June 5; 94(11):855-7
    View PubMed
  141. Qu GZ, Perez EA. Gemcitabine and targeted therapy in metastatic breast cancer. Semin Oncol 2002 Jun; 29(3 Suppl 11):44-52.
    View PubMed
  142. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002 May; 73(1):85-8.
    View PubMed
  143. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002 Mar 15; 20(6):1578-83.
    View PubMed
  144. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002 Feb; 77(2):148-54.
    View PubMed
  145. Mincey BA, Vallow LA, Perez EA. Adjuvant therapy trials of radiotherapy and systemic treatment for breast cancer. Curr Oncol Rep 2002 Jan; 4(1):1.
    View PubMed
  146. Mincey BA, Palmieri FM, Perez EA. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist 2002; 7(3):246-50.
    View PubMed
  147. Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers. Cancer Invest 2002; 20(4):473-9.
    View PubMed
  148. Maihle NJ, Lafky JM, Baron AT, Boardman CH, Greenwood TM, Christensen TA, Reiter JL, Cora EM, Lee H, Suman VJ, Fishman DA, Perez EA, Podratz KC. EGF receptor/ErbB isoforms as serum biomarkers in breast and ovarian cancer. Journal of Clinical Ligand Assay 2002 Spr; 25(1):57-60.
  149. Perez EA. Anti-cancer treatment-12th international congress: Feb 4-7 2002, Paris, France. Idrugs 2002; 5(3):222-3.
    View PubMed
  150. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001 Nov 15; 19(22):4216-23.
    View PubMed
  151. Baron AT, Lafkyk JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev 2001 Nov; 10(11):1175-85.
    View PubMed
  152. Perez EA. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Curr Oncol Rep 2001 Nov; 3(6):516-22.
    View PubMed
  153. Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 2001 Oct; 28(5 Suppl 16):41-6.
    View PubMed
  154. Perez EA. Adjuvant anti-HER2 monoclonal antibody therapy - ready for breast cancer? Breast 2001 Aug; 10(Suppl 3):161-3.
  155. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol 2001 Aug; 28(4 Suppl 12):15-23.
    View PubMed
  156. Perez EA. Metastatic bone disease in breast cancer: the patient's perspective. Semin Oncol 2001 Aug; 28(4 Suppl 11):60-3.
    View PubMed
  157. Mincey BA, Bammer T, Atkinson EJ, Perez EA. Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. Arch Surg 2001 Jul; 136(7):779-82.
    View PubMed
  158. Lara PN Jr, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California cancer consortium trial. Cancer Chemother Pharmacol 2001 Jul; 48(1):22-8.
    View PubMed
  159. Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 2001; 19(2):155-64.
    View PubMed
  160. Perez EA, Romond E. Trastuzumab (Herceptin®) in adjuvant therapy of breast cancer: a summary of current and proposed trials. Biological Therapy of Breast Cancer 2001; 2(4):2-5.
    View PubMed
  161. Perez EA. Incorporation of taxanes in the adjuvant management of patients with breast cancer, incorporating data presented at the 2000 NIH Consensus Development Conference. Advances in Breast Cancer 2001; 3(2):2-5.
  162. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100.
    View PubMed
  163. Rhodes DJ, Hartmann LC, Perez EA. Breast cancer prevention trials. Curr Oncol Rep 2000 Nov; 2(6):558-65.
    View PubMed
  164. Perez EA. Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. Clin Breast Cancer 2000 Sep; 1 Suppl 1:S52-6.
    View PubMed
  165. Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc 2000 Aug; 75(8):821-9.
    View PubMed
  166. Perez E. Review: routine follow-up tests do not improve survival and quality of life in women after treatment for early-stage breast cancer. ACP J Club 2000 May-Jun; 132(3):107.
  167. Perez EA. Tamoxifen added to lumpectomy and radiation therapy reduced breast cancer events in ductal carcinoma in situ. ACP J Club 2000 Mar-Apr; 132(2):54.
  168. Loprinzi CL, Alberts SR, Christensen BJ, Hanson LJ, Farley DR, Broers JK, Betcher DL, Grady RE, Southorn PA, Johnson TM, Perez EA. History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clin Proc 2000 Mar; 75(3):303-9.
    View PubMed
  169. Bonner JA, Sloan JA, Rowland KM Jr, Klee GG, Kugler JW, Mailliard JA, Wiesenfeld M, Krook JE, Maksymiuk AW, Shaw EG, Marks RS, Perez EA. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 2000 Feb; 6(2):597-601.
    View PubMed
  170. Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, Hatfield AK, Mailliard JA, Nair S, Kardinal CG, Ingle JN. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000 Jan 1; 88(1):124-31.
    View PubMed
  171. Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer 2000 Jan; 8(1):46-8.
    View PubMed
  172. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT3 regimen and literature review. Support Care Cancer 1999 Nov; 7(6):413-24.
    View PubMed
  173. Perez EA. 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 1999 Sep; 57(2):207-14.
    View PubMed
  174. Perez EA. Update on metastatic breast cancer. Curr Oncol Rep 1999 Sep; 1(1):11-5.
    View PubMed
  175. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999 Aug; 26(4 Suppl 12):1-10.
    View PubMed
  176. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999 Jul; 162(1):98-102.
    View PubMed
  177. Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999 Jul; 5(7):1642-9.
    View PubMed
  178. Perez EA. Paclitaxel plus nonanthracycline combinations in metastatic breast cancer. Semin Oncol 1999 Feb; 26(1 Suppl 2):21-6.
    View PubMed
  179. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17(9):2971-94.
    View PubMed
  180. Perez EA. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. Cancer Control 1999; 6(3):233-40.
    View PubMed
  181. Perez EA. State of the art management of locally advanced breast cancer. Cancer Research, Therapy & Control 1999; 9(3-4):261-6.
  182. Perez EA. State of the art therapy for metastatic breast cancer. Cancer Research, Therapy & Control 1999; 9(3-4):289-95.
  183. Perez EA, Horton J, Muss HB. Management of bone metastases in advanced breast cancer. Cancer Chemother Pharmacol 1999; 6(5 Suppl):28-31.
    View PubMed
  184. Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res 1998 Nov-Dec; 18(6A):4011-8.
    View PubMed
  185. Perez EA. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest 1998 Aug; 114(2):593-604.
    View PubMed
  186. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998 Jul; 16(7):2377-81.
    View PubMed
  187. Loprinzi CL, Pisansky TM, Fonseca R, Zahasky KM, Quella SK, Sloan JA, Rummans TA, Dumesic DA, Perez EA, Novotny PJ. Vanlafaxine-associated hot flash reduction in cancer survivors. J Clin Oncol 1998 July; 16(7):2377-81.
    View PubMed
  188. Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5HT(3) antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy - dose, schedule, and route of administration. Support Care Cancer 1998 May; 6(3):237-43.
    View PubMed
  189. Perez EA. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. Cancer J Sci Am 1998 Mar-Apr; 4(2):72-7.
    View PubMed
  190. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998 Feb; 16(2):754-60.
    View PubMed
  191. Perez EA. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf 1998 Jan; 18(1):43-56.
    View PubMed
  192. Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1998 Jan-Feb; 4(1):52-8.
    View PubMed
  193. Perez EA, Buckwalter CA. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol 1998; 41(6):448-52.
    View PubMed
  194. Perez EA. Paclitaxel in breast cancer. Oncologist 1998; 3(6):373-89.
    View PubMed
  195. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs 1998; 16(1):69-75.
    View PubMed
  196. Lara PN Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol 1998; 42(6):504-8.
    View PubMed
  197. Perez EA. Preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for acute chemotherapy-induced emesis: A short review. Topics in Supp Care Oncol 1998; 27:8-10.
  198. Perez EA. Appropriate use of 5-HT3-receptor antiemetics. Health Care Innov Special Supplement: Maximizing Antiemetic Outcomes in a Managed Care Environment 1997 Nov/Dec.
  199. Perez EA, Foo ML, Fulmer JT. Management of locally advanced breast cancer. Oncology (Huntington) 1997 Sep; 11(9 Suppl 9):9-17.
    View PubMed
  200. Perez EA, Loprinzi CL, Sloan JA, Owens DT, Novotny PJ, Bonner JA. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer 1997 Aug 15; 80(4):676-80.
    View PubMed
  201. Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH, Fitts D. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 1997 Jan; 5(1):31-7.
    View PubMed
  202. Gandara DR, Crowley J, Livingston RB, Perez EA, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. Classic Papers and Current Comments 1997; 2(1):178-84.
  203. Perez EA, Buckwalter CA, Reid JP. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Semin Oncol 1996 Dec; 23(6 Suppl 15):21-5.
    View PubMed
  204. Perez EA, Hartmann LC. Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol 1996 Oct; 23(5 Suppl 11):41-5.
    View PubMed
  205. Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther 1996 Jul-Aug; 18(4):578-90; discussion 577.
    View PubMed
  206. Perez EA. Managing chemotherapy-induced nausea and vomiting. P T 1996; 21(3 Suppl):5s-14s.
  207. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Dose ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Supp Care Cancer 1996; 4:141-6.
  208. Perez EA, Coe T, Turrell C, Campbell D, Lau D, Gandara DR. Phase I study of paclitaxel and oral etoposide in advanced tumors. Cancer J Sci Am 1996; 2:286-90.
    View PubMed
  209. Perez EA. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting. Semin Oncol 1995 Aug; 22(4 Suppl 10):1-2.
    View PubMed
  210. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995 Apr; 13(4):1036-43.
    View PubMed
  211. Perez EA, Campbell DL, Ryu JK. Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Cancer Invest 1995; 13(6):604-7.
    View PubMed
  212. Gandara DR, Hahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, Perez EA. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13(2):490-6.
    View PubMed
  213. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol 1994 Jun; 21(3 Suppl 5):15-21.
    View PubMed
  214. Perez EA, Gandara DR. Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. Semin Oncol 1994 Jun; 21(3 Suppl 4):2-5.
    View PubMed
  215. Perez EA, Sowray PC, Gardner SL, Gandara DR. Phase I study of high dose cisplatin, ifosfamide, and etoposide. Cancer Chemother Pharmocol 1994; 34:331-4.
  216. Perez EA. Clinical comparative efficacy and safety of 5-HT3 antagonists for chemotherapy induced emesis. Hosp Formul 1994; 29(S5):S18-23.
  217. Perez EA, Hack FM, Fletcher TS, Chou TC. Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. Oncol Res 1994; 6(3):151-6.
    View PubMed
  218. Costa MJ, Stewart G, Perez EA, Goodnight JE. Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction. Diagn Cytopathol 1994; 10(4):357-61.
    View PubMed
  219. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993 May; 11(5):873-8.
    View PubMed
  220. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 1993; 29A(Suppl 1):S35-8.
    View PubMed
  221. Perez EA, Hack FM, Webber LM, Chou TC. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemother Pharmacol 1993; 33(3):245-50.
    View PubMed
  222. Valone FH, Gandara DR, Luce JA, Wall S, Perez EA, Braham N, George M, Letvak L. Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol 1993; 32(3):215-20.
    View PubMed
  223. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol 1992 Aug; 3(Suppl 3):47-50.
    View PubMed
  224. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992 Aug; 19(4 Suppl 10):67-71.
    View PubMed
  225. Perez EA, Hallstone AE. Chemotherapy-induced emesis: prevention and management. Contemp Oncol 1992; 10:34-43.
  226. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C. Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 1991 Jun; 10(3):207-13.
    View PubMed
  227. Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M 3rd, Ahn DK, Phillips T. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys 1991 May; 20(5):1047-52.
    View PubMed
  228. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother 1991 Feb; 10(1):57-62.
    View PubMed
  229. Perez EA, Hesketh PJ, Gandara DR. Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol 1991 Feb; 18(1 Suppl 3):73-80.
    View PubMed
  230. Gandara DR, Perez EA, Weibe V, De Gregorio MW. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol 1991 Feb; 18(1 Suppl 3):49-55.
    View PubMed
  231. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 1990; 10(4):353-65.
    View PubMed
  232. Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1990; 27(3):243-7.
    View PubMed
  233. Stanton TS, Perez EA, Gandara DR. Chemotherapy of metastatic testicular cancer: current status and future prospects. World J Urol 1990; 8:20-6.
  234. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M. Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res 1989 Jul-Aug; 9(4):1121-8.
    View PubMed
  235. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 1989 May 10; 81(10):790-4.
    View PubMed
  236. DeGregorio MW, Gandara DR, Holleran WM, Perez EA, King CC, Wold HG, Montine TJ, Borch RF. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemother Pharmacol 1989; 23(5):276-8.
    View PubMed
  237. Gandara DR, Perez EA, Denham A, Wiebe VJ, DeGregorio MW. Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. Cancer Chemother Pharmacol 1989; 24(2):135-6.
    View PubMed
  238. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med 1988 Jan; 108(1):21-5.
    View PubMed
  239. Gandara DR, Wold HG, Perez EA, Palkuti H, Haburchak D. Platelet function studies in patients receiving mezlocillin. Antibiotics Annual 1988; 1:937-9.
  240. Gandara DR, Perez EA, DeGregorio MW, Borch R. Cisplatin and fluorouracil with or without sodium diethyldithiocarbamate rescue. J Clin Oncol 1988; 6(11):1785-7.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.